Drugs / Ronacaleret
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01802892 | Nov 2012 → Apr 2013 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01466335 | Oct 2011 → Mar 2012 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00651534 | Feb 2008 → ? | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00471237 | May 2007 → Dec 2008 | osteoporosis | GlaxoSmithKline | Terminated | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ronacaleret | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01802892 ↗ |
| Known as | SB-751689 | “A Randomized, Double Blind, Parallel Group, Single Center, Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium...” NCT01466335 ↗1“SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist)” NCT01802892 ↗ |
| Action | Inhibit | “CONTEXT: Ronacaleret, a calcium-sensing receptor antagonist that stimulates PTH release from the parathyroid glands, was evaluated as an oral osteoanabolic agent for the...” PMID 21593114 ↗ May 2011 |
| Route | Oral | “100, 200, 300, or 400 mg oral ronacaleret once daily” PMID 21593114 ↗ May 2011 |